†Compared to original PreserVision AREDS 2 Soft Gel
We share a goal: To reduce the risk of progression to advanced AMD and its associated vision loss. That’s why we’ve worked with the National Eye Institute (NEI) to develop the only formula recommended by the NEI to help reduce progression in patients with moderate to advanced AMD.
PreserVision® contains the exact levels of nutrients recommended by the NEI to help reduce the risk of moderate to advanced AMD progression.
Our collaboration with the NEI spanned two decades of AREDS trials.
Use our order hotline to request PreserVision® AREDS 2 Formula MiniGel or Chewable samples (while supplies last).
Placebo-controlled and randomized, the AREDS and AREDS2 clinical trials spanned two decades and demonstrated that a nutrient formula can help moderate to advanced AMD patients lower their risk of progression.
(We surveyed 200 optometrists and ophthalmologists)
Contains the formulation recommended by the NEI to help lower the risk of moderate to advanced AMD progression.1
Matches the exact levels of key nutrients recommended by the NEI.
No side effects or tolerability issues reported in the AREDS trials.2
How many minutes can you give to each AMD patient? Our patient education website and materials can help you offer maximum support.
Text Size:A−A+